Latest Period
Q1 2026
Security Snapshot
Theriva Biologics, Inc. - Common stock (TOVX) Institutional Ownership
CUSIP: 87164U508
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
19
Shares (Excl. Options)
1,965,271
Price
$0.20
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common stock
- Symbol
- TOVX on NYSE
- Shares outstanding
- 9,600,143
- Price per share
- $0.33
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 1,965,271
- Total reported value
- $385,351
- % of total 13F portfolios
- 0%
- Share change
- +491,755
- Value change
- +$95,191
- Number of holders
- 19
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- TOVX - Theriva Biologics, Inc. - Common stock is tracked under CUSIP 87164U508.
- 19 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 20 to 19 between Q4 2025 and Q1 2026.
- Reported value moved from $272,379 to $385,351.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 19 institutions filings for Q1 2026.
Security key
87164U508
Latest holder period
Q1 2026
13F holders
19
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
TOVX full holder history
Theriva Biologics, Inc. SEC filings
Theriva Biologics, Inc. company facts
Theriva Biologics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 87164U508:
Significant Owners of Theriva Biologics, Inc. - Common stock (TOVX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Matthew Gryga Irrevocable Trust | 7.7% | $300,046 | 739,211 | Jeffrey Matthew Gryga Irrevocable Trust | 24 Oct 2025 | |||
| Empery Asset Management, LP | 5% | -50% | $201,636 | -$179,638 | 504,091 | -47% | Empery Asset Management, LP | 30 Sep 2025 |
| CVI Investments, Inc. | 4.9% | $206,052 | 146,136 | CVI Investments, Inc. | 31 Dec 2024 |
As of 31 Mar 2026, 19 institutional investors reported holding 1,965,271 shares of Theriva Biologics, Inc. - Common stock (TOVX). This represents 20% of the company’s total 9,600,143 outstanding shares.
Top 23 Institutional Shareholders
The largest institutional shareholders of Theriva Biologics, Inc. - Common stock (TOVX) together control 20% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 4.7% | 450,263 | +112% | 0% | $88,161 |
| Virtu Financial LLC | 2.6% | 253,218 | 0% | $50,000 | |
| VANGUARD FIDUCIARY TRUST CO | 2.5% | 241,780 | 0% | 0% | $47,389 |
| UBS Group AG | 2.4% | 225,624 | +18% | 0% | $44,223 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2% | 192,404 | 0% | 0% | $37,711 |
| JANE STREET GROUP, LLC | 1.8% | 177,034 | 0% | $34,664 | |
| Ikarian Capital, LLC | 1.2% | 112,076 | 0% | 0% | $21,944 |
| TWO SIGMA SECURITIES, LLC | 1.1% | 105,241 | +145% | 0% | $20,606 |
| XTX Topco Ltd | 0.99% | 94,620 | +140% | 0% | $18,527 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.29% | 27,646 | 0% | 0% | $5,413 |
| MORGAN STANLEY | 0.25% | 23,602 | -88% | 0% | $4,621 |
| StoneX Group Inc. | 0.23% | 22,280 | -40% | 0% | $4,362 |
| TWO SIGMA INVESTMENTS, LP | 0.16% | 15,441 | -64% | 0% | $3,023 |
| SCHWARZ DYGOS WHEELER INVESTMENT ADVISORS LLC | 0.16% | 15,000 | 0% | 0% | $2,937 |
| BlackRock, Inc. | 0.08% | 7,504 | 0% | 0% | $1,469 |
| CITIGROUP INC | 0.01% | 1,391 | -78% | 0% | $272 |
| SBI Securities Co., Ltd. | 0% | 131 | +122% | 0% | $26 |
| IFP Advisors, Inc | 0% | 11 | 0% | 0% | $2 |
| NFSG Corp | 0% | 5 | 0% | 0% | $1 |
| DRW Securities, LLC | 0% | 0 | -100% | $0 | |
| BARCLAYS PLC | 0% | 0 | -100% | $0 | |
| BANK OF AMERICA CORP /DE/ | 0% | 0 | -100% | $0 | |
| OSAIC HOLDINGS, INC. | 0% | 3 | 0% | $1 |
Institutional Holders of Theriva Biologics, Inc. - Common stock (TOVX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,965,271 | $385,351 | +$95,191 | $0.20 | 19 |
| 2025 Q4 | 1,295,504 | $272,379 | +$158,821 | $0.21 | 20 |
| 2025 Q3 | 437,052 | $177,030 | +$57,424 | $0.41 | 18 |
| 2025 Q2 | 291,012 | $126,275 | +$38,331 | $0.43 | 15 |
| 2025 Q1 | 190,681 | $209,751 | +$165,878 | $1.10 | 10 |
| 2024 Q4 | 34,470 | $60,323 | -$627,703 | $1.75 | 9 |
| 2024 Q3 | 491,424 | $677,871 | +$471,525 | $1.38 | 16 |